Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMS29M4)

Drug Name
TWS-119 Drug Info
Synonyms
TWS119; 601514-19-6; TWS-119; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB
Cross-matching ID
PubChem CID
9549289
ChEBI ID
CHEMBL405759
CAS Number
CAS 601514-19-6
TTD Drug ID
D0T8KR

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.10 0.00e+0 93/133 (69.92%) NDUFB7;ATP6V0E2;CYC1;...
Fanconi anemia pathway 2.08 0.00e+0 36/54 (66.67%) FANCI;RMI1;RAD51C;...
Ribosome 2.04 2.72e-3 113/158 (71.52%) MRPL35;MRPL23;RPL26L1;...
DNA replication 1.99 2.04e-3 34/36 (94.44%) RNASEH2A;POLE2;FEN1;...
Nucleotide excision repair 1.87 9.78e-3 40/47 (85.11%) POLE2;RPA2;RPA3;...
Homologous recombination 1.81 1.22e-2 35/41 (85.37%) RAD51C;RPA2;RPA3;...
Mismatch repair 1.74 3.61e-2 22/23 (95.65%) RPA2;RPA3;RFC4;...
Ras signaling pathway -1.72 1.64e-2 201/232 (86.64%) TGFA;PDGFB;FGFR4;...
Epithelial cell signaling in Helicobacter pylori infect... -1.72 1.70e-2 62/70 (88.57%) RELA;SRC;PTPRZ1;...
Apelin signaling pathway -1.74 1.58e-2 117/137 (85.4%) KLF2;ACTA2;NOTCH3;...
Malaria -1.75 1.59e-2 44/50 (88%) THBS4;SELP;GYPC;...
Breast cancer -1.75 1.57e-2 119/147 (80.95%) HEY1;NOTCH3;CTNNB1;...
Sphingolipid metabolism -1.75 1.63e-2 32/49 (65.31%) B4GALT6;PLPP1;KDSR;...
Prostate cancer -1.77 1.60e-2 93/97 (95.88%) TMPRSS2;NFKBIA;CDKN1B;...
Bladder cancer -1.77 1.53e-2 40/41 (97.56%) RASSF1;THBS1;DAPK3;...
Central carbon metabolism in cancer -1.78 1.39e-2 67/70 (95.71%) HK1;PFKL;TIGAR;...
Gastric cancer -1.78 1.40e-2 122/149 (81.88%) CTNNB1;HGF;TGFBR1;...
Melanoma -1.78 1.41e-2 68/72 (94.44%) MITF;HGF;MAP2K1;...
ECM-receptor interaction -1.79 1.25e-2 80/88 (90.91%) CHAD;CD47;COL9A3;...
Regulation of lipolysis in adipocytes -1.80 1.26e-2 52/55 (94.55%) ADRB2;CGA;IRS1;...
Ovarian steroidogenesis -1.80 1.33e-2 41/51 (80.39%) CYP1B1;HSD3B1;ADCY3;...
Focal adhesion -1.81 1.41e-2 180/201 (89.55%) CRKL;COL9A3;RAPGEF1;...
Pathways in cancer -1.84 1.21e-2 474/531 (89.27%) CALML5;COL4A3;PIM2;...
Small cell lung cancer -1.87 8.89e-3 90/92 (97.83%) TRAF4;ITGA2;LAMA3;...
AGE-RAGE signaling pathway in diabetic complications -1.89 7.84e-3 97/100 (97%) AGER;STAT5B;PLCE1;...
Thyroid cancer -1.89 8.49e-3 36/37 (97.3%) MAP2K1;TCF7L1;TCF7;...
Signaling pathways regulating pluripotency of stem cell... -1.90 8.23e-3 110/143 (76.92%) FZD5;JAK1;KAT6A;...
TGF-beta signaling pathway -1.90 9.06e-3 81/94 (86.17%) ID3;EP300;SMURF1;...
PI3K-Akt signaling pathway -1.91 1.01e-2 317/354 (89.55%) PPP2R2A;TSC1;RAC1;...
Pancreatic cancer -1.91 9.90e-3 75/76 (98.68%) TGFBR1;JAK1;RALGDS;...
Basal cell carcinoma -1.92 1.13e-2 41/63 (65.08%) DVL3;GLI3;GSK3B;...
MicroRNAs in cancer -1.93 1.32e-2 146/310 (47.1%) SERPINB5;TNXB;CDKN1B;...
Adherens junction -1.95 1.13e-2 63/71 (88.73%) ACTB;PARD3;CSNK2A1;...
MAPK signaling pathway -2.03 5.66e-3 272/294 (92.52%) DUSP8;TGFBR1;JUN;...
FoxO signaling pathway -2.04 7.55e-3 118/131 (90.08%) KLF2;BNIP3;IL7R;...
HIF-1 signaling pathway -2.12 5.66e-3 105/109 (96.33%) HK1;PFKL;EIF4EBP1;...
Proteoglycans in cancer -2.14 1.13e-2 172/205 (83.9%) RAC1;SDC2;SMO;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 15uM 3H, 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 15uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 0.06uM - 15uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H